Smart inhalers are also known as connected inhalers and sensors and are mainly used as clip-on sensors, which are attached over a normal inhaler (DPIs, MDIs) or nebulizers for the treatment of asthma and COPD. Smart inhalers as defined in this report are defined as devices providing data wirelessly through cloud, internet, or mobile apps. They track the usage of the dose as and when taken by the patients and also alert the patients through timely reminders. Under the scope of study, the report only considers devices that provides data digitally and excludes devices such as traditional inhalers or which do not use smart inhalers. In addition, these devices are available for commercial use as well as used for research and development are considered in the report.

The global smart inhalers market is segmented under three different scenarios: moderate growth scenario, rapid growth scenario, and diminishing growth scenario.

Market growth is attributed to the increase in air pollution, incidence of respiratory diseases such as asthma and COPD, and healthcare burden, due to higher cases of asthma and COPD. In addition, probable increase in adherence to smart inhalers is an additional factor for the growth. However, high cost of asthma and COPD treatment, limited availability of smart inhalers, and misuse of data are expected to restrain the market growth.

Looking for more information on this market? Request a free sample report https://goo.gl/M6JoEt

Top Investment Pockets:

The smart inhalers industry is based on three different scenarios, and therefore top investment pockets have been mentioned with respect to the moderate growth scenario.

North America accounted for the maximum revenue due to wider availability of smart inhalers coupled with wider government initiatives, growth in demand for advanced technology, and increase in use of mobile phones. These devices directly transfer data related to the medications to the mobile app as well as to the cloud server through the internet. Therefore, higher use of mobile phones coupled with rise in cases of asthma and COPD in this region act as major growth opportunities for the market growth.

Regional and Country Overview:

Europe has emerged as the second preferred market for smart inhaler products. Novartis, AstraZeneca, and Boehringer Ingelheim are key players the European region. Adoption of these inhalers, by hospitals and patients boosts the market growth. Moreover, the European Academy of Allergy & Clinical Immunology is continuously making efforts to increase awareness about asthma and COPD.

In the year 2015, the leading revenue-generating region was North America, whereas Asia-Pacific is projected to grow at a significant CAGR of 65.3% during the forecast period, due to rise in demand for smart inhalers and increase in cases of COPD and asthma. Asia-Pacific is the potential market due to high population base, high disposable incomes, and rise in patient awareness, and increase in prevalence of asthma and COPD.

The Turkish smart inhalers industry was valued at $30 thousand in 2015, and is expected to reach $1,090 thousand by 2022, with a CAGR of 65.3% during the forecast period.

Key Players in the Smart Inhalers Market:

Adherium is the key market player with majority product approvals. However, smart inhalers being a lucrative market, acquisitions & collaborations between the pharmaceutical companies, medical device companies, and manufacturers are increasing to capture market space. Increase in collaborations between pharmaceutical companies and manufacturers, such as collaboration between Adherium & AstraZeneca; and GSK partnering with Propeller Health, have led competition in the industry. Major players have adopted product approval and clinical trials as their key development strategies. Important players operating in this market include Teva Pharmaceutical Industries Ltd. (Gecko Health Innovations), Vectura Group plc., Boehringer Ingelheim GmbH, AstraZeneca plc, Cohero Health, LLC; Propeller Health, OPKO Health, Inc. (Inspiro Medical Ltd.), Adherium Limited, Novartis AG, and GlaxoSmithKline plc.

Key Benefits

Competitive landscape section includes major players operating within the smart inhalers market, with key strategies adopted by them to achieve high monetary value.
The report also provides quantitative as well as qualitative trends to assist the stakeholders to understand the situations prevailing in the market.
Entire projections presented in the report are based on analysis of the current trends and highlight the market potential from 2016 to 2022, both in terms of value and volume.
The report provides an in-depth analysis of the estimated revenues generated by smart inhalers as well as major geographies during the forecast period.
Smart Inhalers Market Key Segments:
By Product
Inhalers
Dry Powder Inhalers (DPIs)
Metered Dose Inhalers (MDIs)
Nebulizers
By Indication
Asthma
COPD
By End User
Patients
R&D
By Geography
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
UAE
Rest of LAMEA
For More Enquiry Visiting @ https://www.alliedmarketresearch.com/purchase-enquiry/1715